Anthracyclines |
Induction of oxidative stress, impaired autophagy, type II topoisomerase poisoning |
Trastuzumab |
Inhibition of epidermal growth factor receptor 2 |
Fluoropyrimidines |
Induction of oxidative stress in cardiomyocytes, vasospasm by favouring endothelial and smooth cell dysfunction, coronary artery thrombosis |
Platinum drugs |
Induction of oxidative stress and of direct damage to cardiomyocytes and mitochondria, platelet aggregation |
Taxanes |
Direct cardiomyocyte and mitochondrial damage, alteration of cell division and microtubule dysfunction, oxidative stress, platelet aggregation, endothelial injury, haemorrhagic myopericarditis |
Vascular endothelial growth factor (VEGF) inhibitors (tyrosine kinase inhibitors, monoclonal antibodies) |
Arterial and venous thrombosis |
Immune checkpoint inhibitors |
Increased CD4 and CD8 lymphocyte infiltration inducing myopericarditis and arrhythmia |
Radiotherapy |
Coronary atherosclerosis and fibrosis by triggering acute and long-term coronary inflammation |